

# World Journal of *Otorhinolaryngology*

*World J Otorhinolaryngol* 2012 February 28; 2 (1): 1-7





# World Journal of Otorhinolaryngology

A peer-reviewed, online, open-access journal of otorhinolaryngology

## Editorial Board

2011-2015

The *World Journal of Otorhinolaryngology* Editorial Board consists of 100 members, representing a team of worldwide experts in otorhinolaryngology. They are from 26 countries, including Australia (1), Austria (1), Belgium (4), Brazil (1), China (4), Colombia (1), Czech Republic (1), Egypt (5), Germany (4), Greece (8), Hungary (1), India (7), Iran (1), Israel (2), Italy (10), Japan (5), New Zealand (1), Poland (1), Singapore (1), South Korea (3), Spain (1), Sweden (1), Switzerland (1), Turkey (14), United Kingdom (3), and United States (18).

### EDITOR-IN-CHIEF

Tsutomu Nakashima, *Nagoya*  
Steven J Wang, *San Francisco*

### GUEST EDITORIAL BOARD MEMBERS

Chao-Cheng Huang, *Kaohsiung*

### MEMBERS OF THE EDITORIAL BOARD



#### Australia

Anne Elizabeth Vertigan, *Newcastle*



#### Austria

Christoph Arnoldner, *Vienna*



#### Belgium

Joris Joris Dirckx, *Antwerp*  
Amr Essam El-Shazly, *Liege*  
Philippe Rombaux, *Brussels*  
Robby Vanspauwen, *Antwerp*



#### Brazil

Maria Cristina Chammas, *Sao Paulo*



#### China

Anna Chishan Kam, *Hong Kong*  
Hua-Bin Li, *Guangzhou*  
Zheng Liu, *Wuhan*



#### Colombia

Luis Miguel Ramirez Aristeguieta, *Medellin*



#### Czech Republic

Jan Vodicka, *Pardubice*



#### Egypt

Tarek Abdelhameed Abulezz, *Sohag*  
Sherifa Ahmed Hamed, *Assiut*  
Emad Ahmed Magdy, *Alexandria*  
Badr Eldin Mostafa, *Cairo*  
Sameh Ibrahim Sersar, *Mansoura*



#### Germany

Carsten Christof Boedeker, *Freiburg*  
Raphael Richard Ciuman, *Gelsenkirchen*  
Jessica Freiherr, *Aachen*  
Markus Hambek, *Frankfurt*



#### Greece

Anna Eleftheriadou, *Rethymnon*  
G Michael-Minas Fragkiadakis, *Heraklion*  
Haralampos Gouveris, *Alexandroupolis*  
Alexander Dimitrios Karatzanis, *Heraklion*  
George I Nossios, *Serres*  
Theodossis S Papavramidis, *Thessaloniki*  
Maria George Riga, *Alexandroupolis*  
Evangelia Tsakiropoulou, *Thessaloniki*



#### Hungary

László Robert Rovó, *Szeged*



#### India

Muthuswamy Dhiwakar, *Coimbatore*  
Prahlaad Duggal, *Amritsar*  
Ajith Kumar U, *Mysore*  
Satish Nair, *Delhi Cantt*  
Vijaya Kumar Narne, *Mysore*  
Ashok Kumar Sinha, *Kolkata*  
Jagdeep S Thakur, *Shimla*



#### Iran

Mohsen Naraghi, *Tehran*



#### Israel

Haim Gavriel, *Zerifin*  
Michael Vaiman, *Bat Yam*



#### Italy

Marco Berlucchi, *Brescia*  
Giovanni Blandino, *Rome*  
Francesco Bussu, *Rome*  
Alessandro De Stefano, *Taranto*  
Alberto Deganello, *Florence*  
Francesco Dispenza, *Palermo*  
Alfio Ferlito, *Udine*  
Stavros D Hatzopoulos, *Ferrara*  
Gino Marioni, *Padova*  
Giacomo Pata, *Brescia*



#### Japan

Arata Horii, *Osaka*  
Sho Kanzaki, *Tokyo*  
Nejat Mahdieh, *Shizuoka*  
Akihiro Shiotani, *Saitama*

**New Zealand**

Srdjan Vlajkovic, *Auckland*

**Poland**

W Wiktor Jedrzejczak, *Warsaw*

**Singapore**

De-Yun Wang, *Singapore*

**South Korea**

Han Su Kim, *Seoul*  
Sang Hag Lee, *Seoul*  
Raekil Park, *Iksan*

**Spain**

Mario A Hermsen, *Oviedo*

**Sweden**

Zhe Jin, *Uppsala*

**Switzerland**

Thomas Nicola Roth, *Zurich*

**Turkey**

Atilla Arslanoglu, *Ankara*  
Murat Caloglu, *Edirne*  
Ali Coskun, *Izmir*  
Alper Nabi Erkan, *Adana*  
Mustafa Gul, *Kahramanmaraş*  
Mehmet Gunduz, *Ankara*  
Samet Vasfi Kuvat, *Istanbul*  
Nuray Bayar Muluk, *Ankara*  
Nesrin Bozdogan Ozyilkan, *Adana*  
Murat Songu, *Izmir*  
Rauf Tahamiler, *Istanbul*  
Murat Unal, *Mersin*  
Sidika Deniz Yalim, *Adana*  
Yavuz Selim Yildirim, *Istanbul*

**United Kingdom**

Ahmed Eweiss, *Gloucester*  
Jonathan Charles Hobson, *Manchester*  
Petros V Vlastarakos, *Stevenage*

**United States**

Ahmed Kamel Abdel Aal, *Birmingham*  
Thomas Jay Balkany, *Miami*  
Samuel S Becker, *Sewell*  
Rakesh Kumar Chandra, *Chicago*  
Nipun Chhabra, *Cleveland*  
Didier A Depireux, *College Park*  
Richard L Doty, *Philadelphia*  
James Paul Dworkin, *Detroit*  
Patrick Kyongmin Ha, *Baltimore*  
Ron B Mitchell, *St Louis*  
Fred A Pereira, *Houston*  
Claus-Peter Richter, *Chicago*  
Peter S Roland, *Dallas*  
Ashok R Shaha, *New York*  
Abraham Shulman, *Brooklyn*  
Gregory Thomas Wolf, *Ann Arbor*  
Kathleen Yaremchuk, *Detroit*

**ORIGINAL ARTICLE****1**Effects of p27<sup>Kip1</sup>- and p53- shRNAs on kanamycin damaged mouse cochlea*Pietola L, Jero J, Jalkanen R, Kinnari TJ, Jero O, Frilander M, Pajusola K, Salminen M, Aarnisalo AA*

## Contents

*World Journal of Otorhinolaryngology*  
Volume 2 Number 1 February 28, 2012

**ACKNOWLEDGMENTS** I Acknowledgments to reviewers of *World Journal of Otorhinolaryngology*

**APPENDIX** I Meetings  
I-V Instructions to authors

**ABOUT COVER** Editor-in-Chief of *World Journal of Otorhinolaryngology*, Tsutomu Nakashima, MD, PhD, Professor, Department of Otorhinolaryngology, Nagoya University Graduate School of Medicine, 65, Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan

**AIM AND SCOPE** *World Journal of Otorhinolaryngology* (*World J Otorhinolaryngol*, *WJO*, online ISSN 2218-6247, DOI: 10.5319) is a bimonthly peer-reviewed, online, open-access (OA), journal supported by an editorial board consisting of 100 experts in otorhinolaryngology from 26 countries.

The aim of *WJO* is to report rapidly new theories, methods and techniques for prevention, diagnosis, treatment, rehabilitation and nursing in the field of otorhinolaryngology. *WJO* covers diagnostic imaging, endoscopy, rhinology, pharyngology, laryngology, tracheo-esophagology, otology, tracheology, cancer, nasal symptomatology, congenital nasal diseases, inflammatory diseases of the external nose, rhinitis, allergic rhinitis, nasal polyps, nasal septal diseases, nasal bleeding, nasal or sinus foreign bodies, sinusitis, rhinogenic complications, traditional medicine, integrated Chinese and Western medicine, evidence-based medicine, epidemiology and nursing. The journal also publishes original articles and reviews that report the results of applied and basic research in fields related to otorhinolaryngology, such as immunology, physiopathology, cell biology, pharmacology, medical genetics, and pharmacology of Chinese herbs.

**FLYLEAF** I-III Editorial Board

## EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Xing Wu*  
Responsible Electronic Editor: *Xing Wu*  
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Xiao-Cui Yang*  
Proofing Editorial Office Director: *Xing Wu*

**NAME OF JOURNAL**  
*World Journal of Otorhinolaryngology*

**ISSN**  
ISSN 2218-6247 (online)

**LAUNCH DATE**  
December 28, 2011

**FREQUENCY**  
Bimonthly

**EDITING**  
Editorial Board of *World Journal of Otorhinolaryngology*  
Room 903, Building D, Ocean International Center,  
No. 62 Dongsihuan Zhonglu, Chaoyang District,  
Beijing 100025, China  
Telephone: +86-10-85381892  
Fax: +86-10-85381893  
E-mail: [wjotorhinolaryngol@wjgnet.com](mailto:wjotorhinolaryngol@wjgnet.com)  
<http://www.wjgnet.com>

**EDITOR-IN-CHIEF**  
**Steven J Wang, MD, FACS, Associate Professor** in  
Residence, Department of Otolaryngology-Head and  
Neck Surgery, University of California, San Francisco,

2233 Post St, 3rd Floor-Box 1225, San Francisco, CA  
94115, United States

**Tsutomu Nakashima, MD, PhD, Professor**, De-  
partment of Otorhinolaryngology, Nagoya University  
Graduate School of Medicine, 65, Tsurumai-cho,  
Showa-ku, Nagoya 466-8550, Japan

**EDITORIAL OFFICE**  
Xing Wu, Assistant Director  
*World Journal of Otorhinolaryngology*  
Room 903, Building D, Ocean International Center,  
No. 62 Dongsihuan Zhonglu, Chaoyang District,  
Beijing 100025, China  
Telephone: +86-10-85381892  
Fax: +86-10-85381893  
E-mail: [wjotorhinolaryngol@wjgnet.com](mailto:wjotorhinolaryngol@wjgnet.com)  
<http://www.wjgnet.com>

**PUBLISHER**  
Baishideng Publishing Group Co., Limited  
Room 1701, 17/F, Henan Building,  
No.90 Jaffe Road, Wanchai, Hong Kong, China  
Fax: +852-31158812  
Telephone: +852-58042046

E-mail: [bpg@baishideng.com](mailto:bpg@baishideng.com)  
<http://www.wjgnet.com>

**PUBLICATION DATE**  
February 28, 2012

**COPYRIGHT**  
© 2011 Baishideng. Articles published by this Open-  
Access journal are distributed under the terms of  
the Creative Commons Attribution Non-commercial  
License, which permits use, distribution, and reproduc-  
tion in any medium, provided the original work is prop-  
erly cited, the use is non commercial and is otherwise in  
compliance with the license.

**SPECIAL STATEMENT**  
All articles published in this journal represent the  
viewpoints of the authors except where indicated oth-  
erwise.

**INSTRUCTIONS TO AUTHORS**  
Full instructions are available online at [http://www.wjgnet.com/2218-6247/g\\_info\\_20100722180338.htm](http://www.wjgnet.com/2218-6247/g_info_20100722180338.htm)

**ONLINE SUBMISSION**  
<http://www.wjgnet.com/2218-6247/office/>



## Effects of p27<sup>Kip1</sup>- and p53- shRNAs on kanamycin damaged mouse cochlea

Laura Pietola, Jussi Jero, Reetta Jalkanen, Teemu J Kinnari, Olga Jero, Mikko Frilander, Katri Pajusola, Marjo Salminen, Antti A Aarnisalo

Laura Pietola, Jussi Jero, Teemu J Kinnari, Olga Jero, Antti A Aarnisalo, Department of Otorhinolaryngology, University of Helsinki, 00014 Helsinki, Finland

Reetta Jalkanen, Folkhälsan Institute of Genetics, Biomedicum Helsinki, 00014 Helsinki, Finland

Mikko Frilander, Institute of Biotechnology, University of Helsinki, 00014 Helsinki, Finland

Katri Pajusola, Molecular Cancer Biology Program, Biomedicum Helsinki, 00014 Helsinki, Finland

Marjo Salminen, Department of Basic Veterinary Science, Division of Biochemistry, University of Helsinki, 00014 Helsinki, Finland

**Author contributions:** Pietola L, Jero J, Jalkanen R, Kinnari TJ, Jero O and Aarnisalo AA performed the research and analyzed the data; Jero J, Salminen M and Aarnisalo AA designed the research; Frilander M and Pajusola K contributed shRNAs and virus vectors; Pietola L, Jero J, Jalkanen R, Salminen M and Aarnisalo AA wrote the paper.

Supported by grants from a Helsinki University Central Hospital Research Funds; the Sigrid Jusélius Foundation; the Instrumentarium Research Foundation; and the Finnish Medical Foundation.

Correspondence to: **Antti A Aarnisalo, MD, PhD**, Department of Otorhinolaryngology, University of Helsinki, 00014 Helsinki, Finland. [antti.aarnisalo@hus.fi](mailto:antti.aarnisalo@hus.fi)

Telephone: +358-9-4711 Fax: +358-9-47175010

Received: March 22, 2011 Revised: November 2, 2011

Accepted: February 27, 2012

Published online: February 28, 2012

### Abstract

**AIM:** To study the effects of adeno-associated virus (AAV) delivered short hairpin RNAs (shRNAs) on adult CD-1 mouse cochlea damaged by aminoglycoside antibiotic kanamycin.

**METHODS:** Three different shRNAs were designed (p27<sup>Kip1</sup>, p53 and p27<sup>Kip1</sup>+p53) and tested in COS cells. A total of 20 adult CD-1 mice were used in the experiment. Mice were divided into five different groups (four

animals/group) depending on the AAV-shRNA construct they received and whether they received kanamycin or not. Saline and AAV-EGFP injected animals were used as controls. All constructs were injected through the round window membrane (RWM) into the cochlea. Cochleae were harvested after 1 mo. Apoptosis was detected with Tunel labeling from paraffin-embedded cochlear tissue sections.

**RESULTS:** AAV2/2-p27<sup>Kip1</sup>-shRNA and AAV2/2-p53-shRNA were tested in COS cells. Western blotting analysis confirmed that both constructs silenced their target genes effectively in the cell culture. AAV2/2-shRNA constructs were injected into the cochlea of CD-1 mice through the intact RWM. Cotransduction of individual AAV2/2-shRNAs with AAV2/2-EGFP resulted in EGFP expression in the organ of Corti. Kanamycin treatment had no effect on the expression pattern of the EGFP. AAV2/2-shRNA treated mice (either with p53 or p27<sup>Kip1</sup> and p53 together) showed fewer apoptotic hair cells in the cochlea than the control group ( $P < 0.05$ ; AAV2/2-p53-shRNA vs saline  $P = 0.00014$ ; AAV2/2-p27+p53-shRNA vs saline  $P = 0.0011$ ). AAV2/2-p27-shRNA injected cochleae showed no significant difference in the number of apoptotic cells when compared to the saline injected cochleae.

**CONCLUSION:** Silencing of p53 protein in the kanamycin treated ears may decrease cell death in the organ of Corti.

© 2012 Baishideng. All rights reserved.

**Key words:** Inner ear; Adeno-associated virus; Short hairpin RNA; p27; p53; Kanamycin; Apoptosis

**Peer reviewers:** Alessandro De Stefano, MD, PhD, FAINOT, "G.d'Annunzio" University of Chieti and Pescara, Via di Palma 10, Taranto 74100, Italy; Dr. Anna Eleftheriadou, MD, PhD, Otolaryngologist Head and Neck Surgeon, Department of Otolaryn-

gology, General Hospital of Rethymnon, Trantalidou Str 15-17, 74100 Rethymnon, Greece

Pietola L, Jero J, Jalkanen R, Kinnari TJ, Jero O, Frilander M, Pajusola K, Salminen M, Aarnisalo AA. Effects of p27<sup>Kip1</sup>- and p53- shRNAs on kanamycin damaged mouse cochlea. *World J Otorhinolaryngol* 2012; 2(1): 1-7 Available from: URL: <http://www.wjgnet.com/2218-6247/full/v2/i1/1.htm> DOI: <http://dx.doi.org/10.5319/wjo.v2.i1.1>

## INTRODUCTION

Specific genes can be efficiently silenced with RNA interference (RNAi). Fire *et al*<sup>[1]</sup> showed in 1998 that double-stranded RNA (dsRNA) can be used in post-transcriptional gene silencing in animals. They also noticed that dsRNA was more effective at producing gene silencing when compared to single-stranded antisense or sense RNA. RNAi can be accomplished by introducing chemically synthesized small interfering RNAs (siRNAs) or vector-based short hairpin RNAs (shRNAs) into living cells<sup>[2,3]</sup>. Adenovirus and adeno-associated virus (AAV) vector based shRNAs have been shown to induce RNAi in neural tissues *in vivo*<sup>[4]</sup>. shRNAs can be delivered into the inner ear by cationic liposomes or different viral vectors (lentivirus, adenovirus or AAV). Transduction efficiency with cationic liposomes is known to be low and the effect is transient<sup>[5,6]</sup>, long-term transfection is possible with adeno-associated and lentiviral vectors<sup>[7-9]</sup>. Long-term, stable expression of shRNAs can be achieved by using RNA polymerase III promoter U6<sup>[10,11]</sup>. The unique sequence specificity of shRNAs makes them suitable to be applied to the inner ear diseases caused by gain of function mutations<sup>[12]</sup>.

Hair cells (HC) in the organ of Corti are terminally differentiated and maintenance of the post-mitotic state is essential for HC survival. Almost all cell divisions in the developing auditory epithelium of mammals and birds stop before birth. Damaged auditory epithelium of birds has an innate capacity to evoke proliferation of supporting cells (SC), which leads to regeneration of new HC<sup>[13]</sup>. HCs in the utricular sensory epithelia of adult guinea pigs and adult humans can proliferate after aminoglycoside damage when maintained *in vitro*. Also, HCs of vestibular sensory epithelia of young guinea pigs are able to regenerate after *in vivo* administration of aminoglycoside antibiotics<sup>[14]</sup>. Despite these observations, HC and SC of the mammalian organ of Corti are quiescent. The majority of mouse cochlear cells become post-mitotic by E14.5<sup>[15]</sup> and the correct cell cycle withdrawal requires cyclin-dependent kinase inhibitor (CKI) p27<sup>Kip1</sup> (also known as Cdkn1b). In newborn and adult mice, p27<sup>Kip1</sup> is expressed in cochlear SCs but not in HCs. In SCs, p27<sup>Kip1</sup> acts as a negative regulator of the G1-S transition in the cell cycle<sup>[16-18]</sup>. The deletion of p27<sup>Kip1</sup> affects the morphology of cochlear sensory cells and all p27<sup>Kip1</sup> knockout mice have severe hearing impairment<sup>[17]</sup>. How-

ever, p27<sup>Kip1</sup> deficient mice have mitotically active cells in postnatal organ of Corti<sup>[16,17]</sup>. p27<sup>Kip1</sup> knockout mice also have supernumerary HC in both outer HC (OHC) and inner HC (IHC) rows<sup>[16]</sup>. While p27<sup>Kip1</sup> is required for the maintenance of the post-mitotic state of the SCs, other CKIs such as p19<sup>Ink4d</sup>, p21<sup>Cip1</sup> and the retinoblastoma tumor suppressor protein (pRb) operate in HCs<sup>[19-21]</sup>. pRb is the primary protein involved in cell cycle regulation in HCs and its function is to repress transcription of genes required for G1-S transition. It is known that inactivation of pRb family members in neurons make the cells re-enter the S-phase. This results in abnormal DNA replication, which is followed by cell death. p53 is a tumor suppressor protein (encoded by the *TP53* gene) which has a major role in DNA damage-induced cell death. When a cell's DNA repair system fails, p53 is phosphorylated and the phosphorylated p53 upregulates Bax, a Bcl-2 family member which takes part in cell death regulation. p53 is also involved in initiating cell death in cochlear and vestibular HC<sup>[22]</sup>. For now, the mechanisms behind the death of neurons and other post-mitotic cells after cell cycle re-entry are poorly known. A recent study by Sulg *et al*<sup>[23]</sup> revealed that misexpression of human papillomavirus-16 E7 oncogene triggered a forced S-phase entry in HCs in explant cultures. They also discovered that DNA damage in OHC following the forced cell cycle entry activated p53 and led to rapid death of the cells. However, utricular cells showed long-term survival after p53 induction and some of the cells progressed into mitosis.

Damage in the mammalian HC is irreversible and leads inevitably to sensorineural hearing loss. Aminoglycoside antibiotics are known to damage primarily the OHCs of the organ of Corti. Aminoglycosides enter the HCs through mechanoelectrical transducer channels. When aminoglycosides are inside HCs, they form aminoglycoside-iron complexes which results in the formation of reactive oxygen species (ROS)<sup>[24]</sup>. ROS are believed to promote apoptotic cell death. Apoptosis of OHCs begins at the basal region of the cochlea and spreads towards the middle and apical zones. IHC and SC are usually less affected<sup>[25]</sup>. It is known that deletion of the p53 offers significant protection against cisplatin-induced HC loss<sup>[22]</sup>. Kaur *et al*<sup>[26]</sup> found that siRNA against transient receptor potential vanilloidin 1 also offers protection against HC loss caused by cisplatin.

Here we have performed AAV2/2 vector mediated delivery of p27<sup>Kip1</sup> and p53 shRNAs into adult mouse cochlea damaged by aminoglycoside antibiotic kanamycin. We investigated the effects of these constructs on the damaged organ of Corti.

## MATERIALS AND METHODS


### ShRNA constructs and cell culture testing

For gene-silencing experiments to produce shRNAs, four different pairs of p27<sup>Kip1</sup> sequences were designed from Genbank BC014296 and NM\_009875 sequences and synthesized (Oligomer, Finland): (1) p27<sup>Kip1</sup> shRNA


1 lower strand: 5'-AATTAAAACTTACCGCCACAC-GAGTCTCGGAGCCGCGGATATCACTCGCG-GCTCCGAGACTCGCGCGGCGGCAAGGGCC-3' and upper strand: 5'-CTTGCCGCGCGCGAGTCTC-GGAGCCGCGAGTGATATCCGCGGCTCCGAGA-CTCGTGTGGCGGTAAGTTTTT-3'; (2) p27<sup>Kip1</sup> shRNA 2 lower strand: 5'-AATTAAAAACAAACGACCACCC-GAGCCGCGAGTAGCGCGGATATCACTCGCGC-TACTGCGGCTCGGCGGTCGCTCGGGGCC-3' and upper strand: CGAGCGACCGCCGAGCCG-CAGTAGCGCGAGTGATATCCGCGCTACTGCG-GCTCGGGTGGTCGTTTGT'TTTT-3'; (3) p27<sup>Kip1</sup> shRNA 3 lower strand: 5'-AATTAAAAACCTCTGC-CATTCGTATCTGCCCTCCAGGGATATCACTCCT-GGAGGGCAGATACGAATGGCAGGAGGGGCC-3' and upper strand: CCTCCTGCCATTTCGTATCT-GCCCTCCAGGAGTGATATCCCTGGAGGGCA-GATACGAATGGCAGGAGGTT'TTTT-3'; and (4) p27<sup>Kip1</sup> shRNA 4 lower strand: 5'-AATTAA-AAAAGTCGCGAAGTTCGAAGAGGATAT-CACTCTCTTCGAAGTTCTGCGACGGCC-3' and upper strand: GTCGCGAAGTTCGAAGAGAGT-GATATCCTCTTCGAAGTTCTGCGACTTTT-3'.

The pairs were annealed and the generated double-stranded DNA fragments were cloned into the pSilencer 1.0-U6 plasmid (Ambion, United States) between *Apa*I and *Eco*RI under the U6-promoter. The silencing effect of the different pairs was tested by transfecting 1 µg of shRNA-plasmid into COS-cells in culture with Lipofectamine or Lipofectamine 2000 (Invitrogen, United States) reagents according to the manufacturer's instructions. Since proliferating COS cells do not express p27<sup>Kip1</sup>, we cotransfected 1 µg of p27<sup>Kip1</sup> cDNA expressing vector together with the shRNA plasmids. Bluescript plasmid (Stratagene, United States) was used as a control. Expression levels of p27<sup>Kip1</sup> in COS cells were analyzed from 10 µg of protein from cell lysates with 12% SDS-PAGE acrylamide gel-electrophoresis, Western blotting using Hybond-C Extra membrane (Pharmacia, United States), rabbit polyclonal anti-p27<sup>Kip1</sup> antibody (1:1000; Santa Cruz, United States) and Anti-rabbit Ig-HRP visualized by ECL Western blotting substrate (Pierce, United States). The best silencing sequences (shRNAs 2 and 3) with their respective U6 promoters were digested out from the pSilencer 1.0-U6 with *Bam*HI and cloned next to each other into the AAV-vector (serotype 2, AAV2/2) in front of the woodchuck hepatitis virus post-transcriptional element (WPRE)<sup>[27]</sup> (Figure 1). The CMV promoter present in the AAV-CMV-WPRE construct<sup>[27]</sup> was removed with *Eco*RI and *Xho*I and uncoding stuffer DNA was cloned instead to keep the viral DNA size optimal (Figure 1).

The following p53 shRNA sequences were designed from GenBank: AF051368 and synthesized (Oligomer): p53 lower strand: 5'-AATTAAAAAGGCCCAAGT-GAAGCCCTCCGAGTGTGATATCACTTAA-CACTCGAAGGGCTCCACTTAGACCGGCC-3' and upper strand: 5'-GGTCTAAGTGGAGCCCTTC-GAGTGTTAAGTGATATCTGACACTCG-GAGGGCTTCACITGGGCCTTTT-3'. As above, the annealed fragment was cloned in pSilencer 1.0-U6 and



**Figure 1 Short hairpin RNA testing in COS cells.** A: Western blot analysis with anti-p27<sup>Kip1</sup> antibody. Proteins were extracted from untransfected COS cells and COS cells transfected with Bluescript (pBS), p27<sup>Kip1</sup> cDNA (p27-cDNA) or p27<sup>Kip1</sup> cDNA together with 4 different p27<sup>Kip1</sup> short hairpin RNA (shRNA) constructs, p27(1-4). p27<sup>Kip1</sup> specific bands are marked on the right side. A decrease in p27<sup>Kip1</sup> level was observed with p27(2), p27(3) and p27(2+3) after 24 h of transfection; B: Western blot analysis with anti-p53 antibody. Proteins were extracted from untransfected COS cells (COS), p53 null cells (p53<sup>-/-</sup>), p53 heterozygous null cells (p53<sup>+/-</sup>), COS cells transfected with p53 shRNA. Cells were collected 24 h or 48 h after transfection. p53 specific bands are marked on the right side. A decrease in p53 level was detected after 24 h of transfection. Kaleidoscope molecular weight (MW) standards are marked on the left side. MEF: Mouse embryonic fibroblasts.



**Figure 2 Schematic representation of used adeno-associated virus constructs.** The constructs are not drawn in scale. ITR: Adeno-associated virus inverted terminal repeats; CMV: Human cytomegalovirus promoter; U6: U6-promoter; EGFP: Enhanced green fluorescent protein coding sequence; shRNA: Small hairpin RNA; 1: shp27Kip1(2)/shp27Kip1(3); 2: shp53; 3: shp53/shp-27Kip1(2)/shp27Kip1(3); WPRE: Woodchuck hepatitis virus post-transcriptional regulatory element; pA: SV40 polyadenylation signal.

tested in COS cells. As controls for Western blotting, mouse embryonic fibroblasts (MEF) from p53 targeted embryos (p53<sup>-/-</sup> and p53<sup>+/-</sup>; Jackson laboratory, United States) were grown. Western blotting analysis was performed as above with anti-p53 antibody (1:300; sc-6243 Santa Cruz).

The U6-p53 fragment from pSilencer 1.0-U6 was cloned into the AAV-vector as above either alone or together with the p27<sup>Kip1</sup> shRNAs 2 and 3 (Figure 1).



**Table 1** Grouping of injected mice (*n* = 20)

| Group | <i>n</i> | Construct         | Kanamycin treatment |
|-------|----------|-------------------|---------------------|
| 1     | 4        | AAV-p27-shRNA     | Yes                 |
| 2     | 4        | AAV-p53-shRNA     | Yes                 |
| 3     | 4        | AAV-p27+p53-shRNA | Yes                 |
| 4     | 4        | Saline            | Yes                 |
| 5     | 4        | AAV-EGFP          | No                  |

AAV: Adeno-associated virus; shRNA: Short hairpin RNA.

### Virus production and transduction

The production of recombinant AAV vectors (Figure 2) was described earlier by Paterna *et al.*<sup>[27]</sup> in 2000.

### Animal surgery and transduction of mice in vivo with AAV-shRNA constructs

Twenty white, 11 wk to 13 wk old male CD-1 mice (weight approx. 30 g, Harlan, Netherlands) were used. The mice were divided into groups (Table 1) according to which AAV2/2-shRNA complex they received: p27<sup>Kip1</sup> (AAV-p27-shRNA), p53 (AAV-p53-shRNA), p27<sup>Kip1</sup>+p53 (AAV-p27+p53-shRNA). These groups were also transduced with the AAV2/2-EGFP. The fourth group received only saline injections. These four groups (16 mice) were pretreated with kanamycin injections 15 d prior to the surgery (Table 1). Each animal received 0.6 mL of kanamycin sulfate (0.02 mL/g daily, 2 × 0.3 mL/d intraperitoneally, i.p., 400 mg/kg, Sigma-Aldrich) daily. The fifth group received only AAV2/2-EGFP injections without kanamycin pretreatment. The animals were anesthetized with an ip injection of ketamine and midazolamine (0.05 mg/10 g body weight). Exposure of the cranial base and middle ear bulla was performed through a ventral paramedian incision as described previously by Jero *et al.*<sup>[28]</sup> in 2001. AAV-shRNA together with AAV-EGFP or saline was introduced into the inner ear of the mice by injecting directly through the round window membrane (RWM). Saline (1 µL) or AAV-shRNA and AAV-EGFP (0.5 + 0.5 µL) was injected into the inner ear with a glass capillary (inner diameter 0.5 mm, SM100F-15, Harvard apparatus, tip diameter 50 µm) with the help of a microinjector (Narishige, Japan) and a preparation microscope (Olympus SZX12). Virus titer was 1 × 10<sup>12</sup> pfu/mL. After the injection, the RWM was sealed with a small piece of thin fascia and the incision was closed in layers. The total operating time was approximately 15-20 min.

### Ethics

Animal care and studies were approved by the Local Ethics Committee of Animal Experiments, University of Helsinki, and by the Provincial State Office of Southern Finland. Animal experiments were conducted in accordance with the European Convention guidelines.

### Sample preparation, immunohistochemistry and statistical analysis

Animals were sacrificed 1 mo after the surgery with an ip overdose of sodium pentobarbital (0.3 mg/10 g, Me-

bunat, Orion, Finland) and perfused transcardially. Inner ears were harvested and postfixed o/n in 4% PFA and decalcified for 14 d in 0.5 mol/L EDTA. The cochleae were mounted in paraffin.

Paraffin-embedded cochlear tissue sections (5 µm) were dewaxed, mounted in fluorescent Vectashield Mounting Medium (Vector Laboratories, United States) under glass coverslips and analyzed for EGFP expression with Axioplan 2 fluorescence microscope (Zeiss).

Apoptosis in the organ of Corti was evaluated with Tunel staining (Roche Applied Science, Germany). Stained slides were mounted in Vectashield Mounting Medium, fluorescence (Vector Laboratories) under glass coverslips. All stained slides were analyzed with Axioplan 2 microscope (Zeiss).

Four animals per group and twenty sections per animal were studied. Results were evaluated statistically using Student's *t* test. Statistical significance was set at *P* < 0.05.

## RESULTS


### Testing of shRNA constructs in COS cells

The different pSilencer 1.0-U6 shRNA constructs were transfected into COS cells with Lipofectamine reagents. Cells were collected and proteins extracted after 24 h or 48 h of incubation. To test the p27<sup>Kip1</sup> constructs, p27<sup>Kip1</sup> cDNA was also cotransfected into COS cells because no p27<sup>Kip1</sup> expression was detected in dividing COS cells (Figure 1A). Western blotting analysis with anti-p27<sup>Kip1</sup> antibody showed that the best silencing was produced with two p27<sup>Kip1</sup>-shRNAs 2 and 3. These two shRNAs were first cloned together into the pSilencer 1.0-U6 vector and tested in COS cells (Figure 1A). After successful testing in COS cells, the two p27<sup>Kip1</sup>-shRNAs were cloned into the AAV2/2 vector<sup>[18]</sup> to give rise to the AAV-p27-shRNA (Figure 1A).


The p53-shRNA was tested in transfections into COS cells which express p53 (Figure 1B). In Western blotting analysis, proteins were also extracted from MEFs isolated from gene targeted p53 null embryos (p53<sup>-/-</sup>) and heterozygous embryos (p53<sup>+/-</sup>). As expected, no p53 was detected in p53<sup>-/-</sup> MEFs, whereas p53<sup>+/-</sup> MEFs showed detectable levels of p53 expression (Figure 1B). The p53 expression in the COS cells was clearly decreased after 24 h of the transfection, whereas after 48 h the level appeared nearly normal (Figure 1B). The p53-shRNA fragment was cloned into the AAV2/2 vector either alone to give rise to the AAV-p53-shRNA or together with the two p27<sup>Kip1</sup>-shRNAs to give rise to AAV-p27+p53-shRNA.

### AAV-shRNAs in mouse cochlea

The AAV2/2-shRNA vectors were injected together with AAV2/2-EGFP into kanamycin pretreated mouse cochlea. After a month, EGFP expression was detected in the cochlea of all injected mice (Figure 3A and B). Expression was limited to the organ of Corti, histologically in both IHC and OHC and in SC, and was detected in all cochlear turns. The expression was, however, most



**Figure 3** Adeno-associated virus-short hairpin RNAs in mouse cochlea. A: EGFP expression in mouse cochlea organ of Corti cotransduced with adeno-associated virus (AAV)-EGFP and AAV-short hairpin RNA (shRNA) (p27<sup>Kip1</sup>+p53). Arrow shows EGFP-positive cell; FITC filter, Scale bar 200  $\mu$ m; B: Uninjected control ear form the AAV-shRNA (p27<sup>Kip1</sup>+p53) injected animal; Arrows point to apoptotic cells in organ of Corti, Scale bar 200  $\mu$ m; C: NaCl injected animal's ear; Arrows point to apoptotic cells in organ of Corti. Scale bar 200  $\mu$ m.



**Figure 4** Number of apoptotic cells in the mouse cochlea after kanamycin treatment and injections with adeno-associated virus-p53-short hairpin RNA and adeno-associated virus-p27 + p53-short hairpin RNA constructs. Differences in the level of apoptosis between adeno-associated virus (AAV)-short hairpin RNA (shRNA) and saline injected cochleae were statistically significant, <sup>a</sup> $P < 0.001$ . AAV-p53-shRNA vs saline  $P = 0.00014$ ; AAV-p27 + p53-shRNA vs saline  $P = 0.0011$ .

intense at the site of injection. One group was injected with AAV2/2-EGFP but did not receive kanamycin injections prior the injections. The expression of EGFP was similar to the other injected mice, so kanamycin had no effect on the expression pattern of the EGFP (data not shown). Apoptosis in the inner ear due to aminoglycoside damage was demonstrated by Tunel staining. Tunel stained cells were detected in all cochlear turns (data not shown). AAV2/2-shRNA injected inner ears showed less apoptotic HC when compared to the contralateral control ear and to the inner ears of saline injected control animals (treated with kanamycin) (Figure 3A-C). AAV-p53-shRNA and AAV-p27+p53-shRNA injected co-

chleae showed significantly less apoptotic cells compared to saline injected cochleae,  $P < 0.05$  (AAV-p53-shRNA *vs* saline  $P = 0.00014$ , AAV-p27+p53-shRNA *vs* saline  $P = 0.0011$ ) (Figure 4,  $P < 0.001$ ). AAV-p27-shRNA injected cochleae showed no significant difference compared to the saline injected cochleae.

## DISCUSSION

In this study, we evaluated the effects of three AAV2/2-mediated shRNAs on mouse cochlea damaged by aminoglycoside antibiotic kanamycin. AAV2/2 was selected as the carrier for shRNAs based AAV vectors properties. AAV vectors have an ability to transduce non-dividing cells. AAV serotype 2/2 can transduce cells of the organ of Corti, especially both IHC and OHC but also the SC<sup>[8]</sup>. AAV vectors are generally safe and cause only minimal damage in the inner ear structures<sup>[8]</sup>. The only limiting factor is the small packaging size of the virus. Approximately only 4.5 kb of foreign DNA can be packaged into the virus capsid. We chose to use AAV2/2 in our study based on our own previous data<sup>[8]</sup>, which had shown that AAV2/2 is suitable for inner ear gene therapy applications. In contrast to adenovirus, AAV generates only minimal immune response and it is primarily a humoral response<sup>[29,30]</sup>. We chose to do the injections through the RWM in order to be sure that the vector constructs were delivered to scala tympani. The surgery can cause damage to the inner ear and affect hearing, even although a previous study suggests that the direct microinjection through RWM causes only minimal damage and minor changes in the cochlear cytoarchitecture<sup>[28]</sup>.

Possible damage to hearing was not evaluated in this study.

Created shRNAs were first tested in a COS cell culture. Both shRNAs (p27<sup>Kip1</sup> and p53) were successful in silencing their target genes in COS cells. **These results suggest that the p27<sup>Kip1</sup>-shRNAs 2 and 3 can be used in cells in order to silence p27<sup>Kip1</sup>, and that the p53-shRNA can be used for silencing experiments in cells.** Results from cell culture experiments led us to believe that p27<sup>Kip1</sup>-and p53-shRNAs may also be used in silencing experiments in the cells of auditory epithelium. We hypothesized that silencing of p27<sup>Kip1</sup> and p53 could improve cell survival in cochlea. The HC loss caused by kanamycin was evaluated with Tunel staining, which specifically stains apoptotic cells at various stages. Kanamycin injections led to apoptosis in cochlear auditory epithelium. Apoptotic HC were seen throughout the cochlea. Kanamycin has been used with CBA, C57Bl6 and BALB mouse strains<sup>[31]</sup>. In this study, we used CD-1 mouse strain. With the CD-1 strain, kanamycin caused both IHC and OHC loss and was consistent with earlier studies with other mouse strains<sup>[31]</sup>. AAV-p53- and AAV-p27<sup>Kip1</sup>+p53-shRNA treated ears showed less apoptotic HC when compared to the saline injected control ears. AAV-p27-shRNA alone had no significant effect to the number of apoptotic cells in the organ of Corti when compared to contralateral control ear or saline injected (kanamycin treated) ear. The combination of p27<sup>Kip1</sup> and p53 shRNAs did not decrease the number of apoptotic cells compared to AAV-p53-shRNA alone. This suggests that silencing of p53 in the kanamycin treated ear may decrease cell death in cochlear auditory epithelium.

The influence of shRNAs to the function of auditory epithelium was not studied. It is currently not known if these shRNAs have an effect on hearing *in vivo*. This needs to be studied in future.

In conclusion, shRNAs can be used in silencing genes in the cell of inner ear. Silencing of p53 in the kanamycin treated ears seems to decrease cell death in the organ of Corti.

## ACKNOWLEDGMENTS

We are grateful to Raija Savolainen for the help with DNA-constructs, Western blottings and cell culture.

## COMMENTS

### Background

Hair cells (HC) in the organ of Corti are terminally differentiated and maintenance of the post-mitotic state is essential for HC survival. **Almost all cell divisions in the developing auditory epithelium of mammals and birds stop before birth.** The majority of mouse cochlear cells become post-mitotic by embryonic day 14.5 and the correct cell cycle withdrawal requires cyclin-dependent kinase inhibitor p27<sup>Kip1</sup> (also known as Cdkn1b). p53 is a tumor suppressor protein which has a major role in DNA damage-induced cell death. p53 is also involved in initiating cell death in cochlear and vestibular HC. For now, the mechanisms behind the death of neurons and other post-mitotic cells after cell cycle re-entry are poorly known. Damage in the mammalian HC is irreversible and leads inevitably to sensorineural hearing loss. Aminoglycoside antibiotics are known

to damage primarily the outer HC of the organ of Corti. It is known that deletion of the p53 offers significant protection against cisplatin (chemotherapy drug) induced HC loss.

### Research frontiers

HC and supporting cells of the mammalian organ of Corti are quiescent. Damage in these cells is irreversible and leads inevitably to sensorineural hearing loss. The main focus of the research is in finding a way to save the HC from trauma, make HC enter the cell cycle again, regenerate HC after cell death, and find a suitable carrier for inner ear gene transfer applications. Cochlear gene therapy studies are, at the moment, focused on the use of different types of vectors (viral and nonviral) as transgene carriers. Each viral vector possesses its own characteristics that limit their use in different applications. At the moment, there is no single vector that would be suitable for each cochlear gene therapy application.

### Innovations and breakthroughs

In this study, we evaluated the effects of three adeno-associated virus (AAV)-short hairpin RNAs (shRNAs) on mouse cochlea damaged by aminoglycoside antibiotic kanamycin. Created shRNAs were first tested in a COS cell culture. Both shRNAs (p27<sup>Kip1</sup> and p53) were successful in silencing their target genes in COS cells. **These results suggest that both shRNA can be used for silencing experiments in cells.** Results from cell culture experiments led us to believe that p27<sup>Kip1</sup>-and p53-shRNAs may also be used to silence the expression of these genes in the cells of auditory epithelium. The study hypothesized that the silencing of p53 could improve cell survival in cochlea. It found that AAV-p53- and AAV-p27<sup>Kip1</sup>+p53-shRNA treated ears showed less apoptotic HC when compared to the saline injected control ears. So, shRNAs can be used in silencing genes in the cell of inner ear. Silencing of p53 in the kanamycin treated ears seems to decrease cell death in the organ of Corti.

### Applications

This study suggests that AAV-shRNAs are promising tools for promoting cell survival in damaged cochlea.

### Terminology

shRNA is a short sequence of RNA that makes a tight hairpin turn that can be used to silence gene expression via RNA interference. AAV: AAV belongs to the genus *Dependovirus*, which in turn belongs to the family *Parvoviridae*. It is a small, replication-defective, non-enveloped virus. AAV can infect both dividing and non-dividing cells and may incorporate its genome into that of the host cell. These features make AAV a good candidate for creating viral vectors for gene therapy. p27<sup>Kip1</sup> is an enzyme that in humans encodes a protein which belongs to the *Cip/Kip* family of cyclin dependent kinase (Cdk) inhibitor proteins. These proteins control the cell cycle re-entry. It is often called a cell cycle inhibitor protein because its major function is to stop or slow down the cell division cycle. p53 is a tumor suppressor protein. p53 regulates the cell cycle and functions as a tumor suppressor that is involved in preventing cancer. p53 has a role in conserving stability by preventing genome mutation. Kanamycin sulfate: is an aminoglycoside antibiotic, available in oral, intravenous and intramuscular forms. It is used to treat a wide variety of infections. Serious side effects include tinnitus or hearing loss, toxicity to kidneys and allergic reactions to the drug.

### Peer review

The paper is well written and well designed. This study describes a very interesting topic. The effects of kanamycin on the cochlea have been well studied in the current literature, as well as the role of p53 and p27.

## REFERENCES

- 1 Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in *Caenorhabditis elegans*. *Nature* 1998; **391**: 806-811
- 2 Pushparaj PN, Aarthi JJ, Manikandan J, Kumar SD. siRNA, miRNA, and shRNA: in vivo applications. *J Dent Res* 2008; **87**: 992-1003
- 3 Rao DD, Vorhies JS, Senzer N, Nemunaitis J. siRNA vs. shRNA: similarities and differences. *Adv Drug Deliv Rev* 2009; **61**: 746-759
- 4 Xia H, Mao Q, Paulson HL, Davidson BL. siRNA-mediated gene silencing in vitro and in vivo. *Nat Biotechnol* 2002; **20**: 1006-1010



- 5 **Jero J**, Mhatre AN, Tseng CJ, Stern RE, Coling DE, Goldstein JA, Hong K, Zheng WW, Hoque AT, Lalwani AK. Cochlear gene delivery through an intact round window membrane in mouse. *Hum Gene Ther* 2001; **12**: 539-548
- 6 **Wareing M**, Mhatre AN, Pettis R, Han JJ, Haut T, Pfister MH, Hong K, Zheng WW, Lalwani AK. Cationic liposome mediated transgene expression in the guinea pig cochlea. *Hear Res* 1999; **128**: 61-69
- 7 **Han JJ**, Mhatre AN, Wareing M, Pettis R, Gao WQ, Zufferey RN, Trono D, Lalwani AK. Transgene expression in the guinea pig cochlea mediated by a lentivirus-derived gene transfer vector. *Hum Gene Ther* 1999; **10**: 1867-1873
- 8 **Aarnisalo AA**, Pietola L, Joensuu J, Isosomppi J, Aarnisalo P, Dinculescu A, Lewin AS, Flannery J, Hauswirth WW, Sankila EM, Jero J. Anti-clarin-1 AAV-delivered ribozyme induced apoptosis in the mouse cochlea. *Hear Res* 2007; **230**: 9-16
- 9 **Pietola L**, Aarnisalo AA, Joensuu J, Pellinen R, Wahlfors J, Jero J. HOX-GFP and WOX-GFP lentivirus vectors for inner ear gene transfer. *Acta Otolaryngol* 2008; **128**: 613-620
- 10 **Sui G**, Soohoo C, Affar el B, Gay F, Shi Y, Forrester WC, Shi Y. A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. *Proc Natl Acad Sci USA* 2002; **99**: 5515-5520
- 11 **Yu JY**, DeRuiter SL, Turner DL. RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. *Proc Natl Acad Sci USA* 2002; **99**: 6047-6052
- 12 **Maeda Y**, Sheffield AM, Smith RJ. Therapeutic regulation of gene expression in the inner ear using RNA interference. *Adv Otorhinolaryngol* 2009; **66**: 13-36
- 13 **Corwin JT**, Cotanche DA. Regeneration of sensory hair cells after acoustic trauma. *Science* 1988; **240**: 1772-1774
- 14 **Warchol ME**, Lambert PR, Goldstein BJ, Forge A, Corwin JT. Regenerative proliferation in inner ear sensory epithelia from adult guinea pigs and humans. *Science* 1993; **259**: 1619-1622
- 15 **Ruben RJ**. Development of the inner ear of the mouse: a radioautographic study of terminal mitoses. *Acta Otolaryngol* 1967; **Suppl 220**: 1-22044
- 16 **Chen P**, Segil N. p27(Kip1) links cell proliferation to morphogenesis in the developing organ of Corti. *Development* 1999; **126**: 1581-1590
- 17 **Löwenheim H**, Furness DN, Kil J, Zinn C, Gültig K, Fero ML, Frost D, Gummer AW, Roberts JM, Rubel EW, Hackney CM, Zenner HP. Gene disruption of p27(Kip1) allows cell proliferation in the postnatal and adult organ of Corti. *Proc Natl Acad Sci USA* 1999; **96**: 4084-4088
- 18 **Harper JW**. Protein destruction: adapting roles for Cks proteins. *Curr Biol* 2001; **11**: R431-R435
- 19 **Chen P**, Zindy F, Abdala C, Liu F, Li X, Roussel MF, Segil N. Progressive hearing loss in mice lacking the cyclin-dependent kinase inhibitor Ink4d. *Nat Cell Biol* 2003; **5**: 422-426
- 20 **Sage C**, Huang M, Karimi K, Gutierrez G, Vollrath MA, Zhang DS, García-Añoveros J, Hinds PW, Corwin JT, Corey DP, Chen ZY. Proliferation of functional hair cells in vivo in the absence of the retinoblastoma protein. *Science* 2005; **307**: 1114-1118
- 21 **Mantela J**, Jiang Z, Ylikoski J, Fritzsche B, Zacksenhaus E, Pirvola U. The retinoblastoma gene pathway regulates the postmitotic state of hair cells of the mouse inner ear. *Development* 2005; **132**: 2377-2388
- 22 **Cheng AG**, Cunningham LL, Rubel EW. Mechanisms of hair cell death and protection. *Curr Opin Otolaryngol Head Neck Surg* 2005; **13**: 343-348
- 23 **Sulg M**, Kirjavainen A, Pajusola K, Bueler H, Ylikoski J, Laiho M, Pirvola U. Differential sensitivity of the inner ear sensory cell populations to forced cell cycle re-entry and p53 induction. *J Neurochem* 2010; **112**: 1513-1526
- 24 **Rybak LP**, Ramkumar V. Ototoxicity. *Kidney Int* 2007; **72**: 931-935
- 25 **Murillo-Cuesta S**, Contreras J, Cediell R, Varela-Nieto I. Comparison of different aminoglycoside antibiotic treatments to refine ototoxicity studies in adult mice. *Lab Anim* 2010; **44**: 124-131
- 26 **Kaur T**, Mukherjee D, Sheehan K, Jajoo S, Rybak LP, Ramkumar V. Short interfering RNA against STAT1 attenuates cisplatin-induced ototoxicity in the rat by suppressing inflammation. *Cell Death Dis* 2011; **2**: e180
- 27 **Paterna JC**, Moccetti T, Mura A, Feldon J, Büeler H. Influence of promoter and WHV post-transcriptional regulatory element on AAV-mediated transgene expression in the rat brain. *Gene Ther* 2000; **7**: 1304-1311
- 28 **Jero J**, Tseng CJ, Mhatre AN, Lalwani AK. A surgical approach appropriate for targeted cochlear gene therapy in the mouse. *Hear Res* 2001; **151**: 106-114
- 29 **Xiao X**, Li J, McCown TJ, Samulski RJ. Gene transfer by adeno-associated virus vectors into the central nervous system. *Exp Neurol* 1997; **144**: 113-124
- 30 **Song S**, Morgan M, Ellis T, Poirier A, Chesnut K, Wang J, Brantly M, Muzyczka N, Byrne BJ, Atkinson M, Flotte TR. Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors. *Proc Natl Acad Sci USA* 1998; **95**: 14384-14388
- 31 **Wu WJ**, Sha SH, McLaren JD, Kawamoto K, Raphael Y, Schacht J. Aminoglycoside ototoxicity in adult CBA, C57BL and BALB mice and the Sprague-Dawley rat. *Hear Res* 2001; **158**: 165-178

S- Editor Wu X L- Editor Roemmele A E- Editor Zheng XM





## ACKNOWLEDGMENTS

## Acknowledgments to reviewers of *World Journal of Otorhinolaryngology*

Many reviewers have contributed their expertise and time to the peer review, a critical process to ensure the quality of *World Journal of Otorhinolaryngology*. The editors and authors of the articles submitted to the journal are grateful to the following reviewers for evaluating the articles (including those published in this issue and those rejected for this issue) during the last editing time period.

**Alessandro De Stefano, MD, PhD, FAINOT**, “G.d’Annunzio”  
University of Chieti and Pescara, Via di Palma 10, Taranto  
74100, Italy

**Dr. Anna Eleftheriadou MD, PhD**, Otolaryngologist  
Head and Neck Surgeon, Department of Otolaryngology,  
General Hospital of Rethymnon, Trantalidou Str 15-17, 74100  
Rethymnon, Greece

**Nuray Bayar Muluk, MD, Professor**, Faculty of Medicine,  
Otorhinolaryngology Department, Kirikkale University, Birlik  
Mahallesi, Zirvekent 2. Etap Sitesi, C-3 blok, No. 62/43, 06610  
Çankaya / Ankara, Turkey

**Dr. Srdjan Vlajkovic, MD, PhD**, Department of Physiology,  
The University of Auckland, Private Bag 92019, Auckland  
1142, New Zealand



## GENERAL INFORMATION

*World Journal of Otorhinolaryngology* (*World J Otorhinolaryngol*, *WJO*, online ISSN 2218-6247, DOI: 10.5319) is a bimonthly peer-reviewed, online, open-access (OA), journal supported by an editorial board consisting of 100 experts in otorhinolaryngology from 26 countries.

The biggest advantage of the OA model is that it provides free, full-text articles in PDF and other formats for experts and the public without registration, which eliminates the obstacle that traditional journals possess and usually delays the speed of the propagation and communication of scientific research results. The open access model has been proven to be a true approach that may achieve the ultimate goal of the journals, i.e. the maximization of the value to the readers, authors and society.

### Maximization of personal benefits

The role of academic journals is to exhibit the scientific levels of a country, a university, a center, a department, and even a scientist, and build an important bridge for communication between scientists and the public. As we all know, the significance of the publication of scientific articles lies not only in disseminating and communicating innovative scientific achievements and academic views, as well as promoting the application of scientific achievements, but also in formally recognizing the "priority" and "copyright" of innovative achievements published, as well as evaluating research performance and academic levels. So, to realize these desired attributes of *WJO* and create a well-recognized journal, the following four types of personal benefits should be maximized. The maximization of personal benefits refers to the pursuit of the maximum personal benefits in a well-considered optimal manner without violation of the laws, ethical rules and the benefits of others. (1) Maximization of the benefits of editorial board members: The primary task of editorial board members is to give a peer review of an unpublished scientific article via online office system to evaluate its innovativeness, scientific and practical values and determine whether it should be published or not. During peer review, editorial board members can also obtain cutting-edge information in that field at first hand. As leaders in their field, they have priority to be invited to write articles and publish commentary articles. We will put peer reviewers' names and affiliations along with the article they reviewed in the journal to acknowledge their contribution; (2) Maximization of the benefits of authors: Since *WJO* is an open-access journal, readers around the world can immediately download and read, free of charge, high-quality, peer-reviewed articles from *WJO* official website, thereby realizing the goals and significance of the communication between authors and peers as well as public reading; (3) Maximization of the benefits of readers: Readers can read or use, free of charge, high-quality peer-reviewed articles without any limits, and cite the arguments, viewpoints, concepts, theories, methods, results, conclusion or facts and data of pertinent literature so as to validate the innovativeness, scientific and practical values of their own research achievements, thus ensuring that their articles have novel arguments or viewpoints, solid evidence and correct conclusion; and (4) Maximization of the benefits of employees: It is an iron law that a first-class journal is unable to exist without first-class editors, and only first-class editors can create a first-class academic journal. We insist on strengthening our team cultivation and construction so that every employee, in an open, fair and transparent environment, could contribute their

wisdom to edit and publish high-quality articles, thereby realizing the maximization of the personal benefits of editorial board members, authors and readers, and yielding the greatest social and economic benefits.

### Aims and scope

The aim of *WJO* is to report rapidly new theories, methods and techniques for prevention, diagnosis, treatment, rehabilitation and nursing in the field of otorhinolaryngology. *WJO* covers diagnostic imaging, endoscopy, rhinology, pharyngology, laryngology, tracheo-esophagology, otology, tracheology, cancer, nasal symptomatology, congenital nasal diseases, inflammatory diseases of the external nose, rhinitis, allergic rhinitis, nasal polyps, nasal septal diseases, nasal bleeding, nasal or sinus foreign bodies, sinusitis, rhinogenic complications, traditional medicine, integrated Chinese and Western medicine, evidence-based medicine, epidemiology and nursing. The journal also publishes original articles and reviews that report the results of applied and basic research in fields related to otorhinolaryngology, such as immunology, physiopathology, cell biology, pharmacology, medical genetics, and pharmacology of Chinese herbs.

### Columns

The columns in the issues of *WJO* will include: (1) Editorial: To introduce and comment on the substantial advance and its importance in the fast-developing areas; (2) Frontier: To review the most representative achievements and comment on the current research status in the important fields, and propose directions for the future research; (3) Topic Highlight: This column consists of three formats, including (A) 10 invited review articles on a hot topic, (B) a commentary on common issues of this hot topic, and (C) a commentary on the 10 individual articles; (4) Observation: To update the development of old and new questions, highlight unsolved problems, and provide strategies on how to solve the questions; (5) Guidelines for Clinical Practice: To provide guidelines for clinical diagnosis and treatment; (6) Review: To systemically review the most representative progress and unsolved problems in the major scientific disciplines, comment on the current research status, and make suggestions on the future work; (7) Original Articles: To originally report the innovative and valuable findings in otorhinolaryngology; (8) Brief Articles: To briefly report the novel and innovative findings in otorhinolaryngology; (9) Case Report: To report a rare or typical case; (10) Letters to the Editor: To discuss and make reply to the contributions published in *WJO*, or to introduce and comment on a controversial issue of general interest; (11) Book Reviews: To introduce and comment on quality monographs of otorhinolaryngology; and (12) Guidelines: To introduce consensus and guidelines reached by international and national academic authorities worldwide on the research in otorhinolaryngology.

### Name of journal

*World Journal of Otorhinolaryngology*

### ISSN

ISSN 2218-6247 (online)

### Editor-in-chief

**Steven J Wang, MD, FACS, Associate Professor** in Residence, Department of Otolaryngology-Head and Neck Surgery, University of California, San Francisco, 2233 Post St, 3rd Floor-Box 1225, San Francisco, CA 94115, United States

## Instructions to authors

**Tsutomu Nakashima, MD, PhD, Professor**, Department of Otorhinolaryngology, Nagoya University Graduate School of Medicine, 65, Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan

### Editorial office

*World Journal of Otorhinolaryngology*

Room 903, Building D, Ocean International Center,

No. 62 Dongsihuan Zhonglu, Chaoyang District,

Beijing 100025, China

Telephone: +86-10-85381892

Fax: +86-10-85381893

E-mail: [wjotorhinolaryngol@wjnet.com](mailto:wjotorhinolaryngol@wjnet.com)

<http://www.wjnet.com>

### Indexed and abstracted in

Digital Object Identifier

### Published by

Baishideng Publishing Group Co., Limited

## SPECIAL STATEMENT

All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

### Biostatistical editing

Statistical review is performed after peer review. We invite an expert in Biomedical Statistics from to evaluate the statistical method used in the paper, including *t*-test (group or paired comparisons), chi-squared test, Riddit, probit, logit, regression (linear, curvilinear, or stepwise), correlation, analysis of variance, analysis of covariance, *etc.* The reviewing points include: (1) Statistical methods should be described when they are used to verify the results; (2) Whether the statistical techniques are suitable or correct; (3) Only homogeneous data can be averaged. Standard deviations are preferred to standard errors. Give the number of observations and subjects (*n*). Losses in observations, such as drop-outs from the study should be reported; (4) Values such as ED50, LD50, IC50 should have their 95% confidence limits calculated and compared by weighted probit analysis (Bliss and Finney); and (5) The word 'significantly' should be replaced by its synonyms (if it indicates extent) or the *P* value (if it indicates statistical significance).

### Conflict-of-interest statement

In the interests of transparency and to help reviewers assess any potential bias, *WJO* requires authors of all papers to declare any competing commercial, personal, political, intellectual, or religious interests in relation to the submitted work. Referees are also asked to indicate any potential conflict they might have reviewing a particular paper. Before submitting, authors are suggested to read "Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Ethical Considerations in the Conduct and Reporting of Research: Conflicts of Interest" from International Committee of Medical Journal Editors (ICMJE), which is available at: [http://www.icmje.org/ethical\\_4conflicts.html](http://www.icmje.org/ethical_4conflicts.html).

Sample wording: [Name of individual] has received fees for serving as a speaker, a consultant and an advisory board member for [names of organizations], and has received research funding from [names of organization]. [Name of individual] is an employee of [name of organization]. [Name of individual] owns stocks and shares in [name of organization]. [Name of individual] owns patent [patent identification and brief description].

### Statement of informed consent

Manuscripts should contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee or it should be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted. Authors should also draw attention to the Code of Ethics of the World Medi-

cal Association (Declaration of Helsinki, 1964, as revised in 2004).

### Statement of human and animal rights

When reporting the results from experiments, authors should follow the highest standards and the trial should conform to Good Clinical Practice (for example, US Food and Drug Administration Good Clinical Practice in FDA-Regulated Clinical Trials; UK Medicines Research Council Guidelines for Good Clinical Practice in Clinical Trials) and/or the World Medical Association Declaration of Helsinki. Generally, we suggest authors follow the lead investigator's national standard. If doubt exists whether the research was conducted in accordance with the above standards, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study.

Before submitting, authors should make their study approved by the relevant research ethics committee or institutional review board. If human participants were involved, manuscripts must be accompanied by a statement that the experiments were undertaken with the understanding and appropriate informed consent of each. Any personal item or information will not be published without explicit consents from the involved patients. If experimental animals were used, the materials and methods (experimental procedures) section must clearly indicate that appropriate measures were taken to minimize pain or discomfort, and details of animal care should be provided.

## SUBMISSION OF MANUSCRIPTS

Manuscripts should be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Number all pages consecutively, and start each of the following sections on a new page: Title Page, Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgements, References, Tables, Figures, and Figure Legends. Neither the editors nor the publisher are responsible for the opinions expressed by contributors. Manuscripts formally accepted for publication become the permanent property of Baishideng Publishing Group Co., Limited, and may not be reproduced by any means, in whole or in part, without the written permission of both the authors and the publisher. We reserve the right to copy-edit and put onto our website accepted manuscripts. Authors should follow the relevant guidelines for the care and use of laboratory animals of their institution or national animal welfare committee. For the sake of transparency in regard to the performance and reporting of clinical trials, we endorse the policy of the ICMJE to refuse to publish papers on clinical trial results if the trial was not recorded in a publicly-accessible registry at its outset. The only register now available, to our knowledge, is <http://www.clinicaltrials.gov> sponsored by the United States National Library of Medicine and we encourage all potential contributors to register with it. However, in the case that other registers become available you will be duly notified. A letter of recommendation from each author's organization should be provided with the contributed article to ensure the privacy and secrecy of research is protected.

Authors should retain one copy of the text, tables, photographs and illustrations because rejected manuscripts will not be returned to the author(s) and the editors will not be responsible for loss or damage to photographs and illustrations sustained during mailing.

### Online submissions

Manuscripts should be submitted through the Online Submission System at: <http://www.wjnet.com/2218-6247/office/>. Authors are highly recommended to consult the ONLINE INSTRUCTIONS TO AUTHORS ([http://www.wjnet.com/2218-6247/g\\_info\\_20100722180338.htm](http://www.wjnet.com/2218-6247/g_info_20100722180338.htm)) before attempting to submit online.

For assistance, authors encountering problems with the Online Submission System may send an email describing the problem to [wjotorhinolaryngol@wjnet.com](mailto:wjotorhinolaryngol@wjnet.com), or by telephone: +86-10-85381892. If you submit your manuscript online, do not make a postal contribution. Repeated online submission for the same manuscript is strictly prohibited.

## MANUSCRIPT PREPARATION

All contributions should be written in English. All articles must be submitted using word-processing software. All submissions must be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Style should conform to our house format. Required information for each of the manuscript sections is as follows:

### Title page

**Title:** Title should be less than 12 words.

**Running title:** A short running title of less than 6 words should be provided.

**Authorship:** Authorship credit should be in accordance with the standard proposed by ICMJE, based on (1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3.

**Institution:** Author names should be given first, then the complete name of institution, city, province and postcode. For example, Xu-Chen Zhang, Li-Xin Mei, Department of Pathology, Chengde Medical College, Chengde 067000, Hebei Province, China. One author may be represented from two institutions, for example, George Sgourakis, Department of General, Visceral, and Transplantation Surgery, Essen 45122, Germany; George Sgourakis, 2nd Surgical Department, Korgialenio-Benakio Red Cross Hospital, Athens 15451, Greece

**Author contributions:** The format of this section should be: Author contributions: Wang CL and Liang L contributed equally to this work; Wang CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the research; Wang CL, Zou CC, Hong F and Wu XM performed the research; Xue JZ and Lu JR contributed new reagents/analytic tools; Wang CL, Liang L and Fu JF analyzed the data; and Wang CL, Liang L and Fu JF wrote the paper.

**Supportive foundations:** The complete name and number of supportive foundations should be provided, e.g. Supported by National Natural Science Foundation of China, No. 30224801

**Correspondence to:** Only one corresponding address should be provided. Author names should be given first, then author title, affiliation, the complete name of institution, city, postcode, province, country, and email. All the letters in the email should be in lower case. A space interval should be inserted between country name and email address. For example, Montgomery Bissell, MD, Professor of Medicine, Chief, Liver Center, Gastroenterology Division, University of California, Box 0538, San Francisco, CA 94143, United States. montgomery.bissell@ucsf.edu

**Telephone and fax:** Telephone and fax should consist of +, country number, district number and telephone or fax number, e.g. Telephone: +86-10-85381892 Fax: +86-10-85381893

**Peer reviewers:** All articles received are subject to peer review. Normally, three experts are invited for each article. Decision for acceptance is made only when at least two experts recommend an article for publication. Reviewers for accepted manuscripts are acknowledged in each manuscript, and reviewers of articles which were not accepted will be acknowledged at the end of each issue. To ensure the quality of the articles published in *WJO*, reviewers of accepted manuscripts will be announced by publishing the name, title/position and institution of the reviewer in the footnote accompanying the printed article. For example, reviewers: Professor Jing-Yuan Fang, Shanghai Institute of Digestive Disease, Shanghai, Affiliated Renji Hospital, Medical Faculty, Shanghai Jiaotong University, Shanghai, China; Professor Xin-Wei Han, Department of

Radiology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan Province, China; and Professor Anren Kuang, Department of Nuclear Medicine, Huaxi Hospital, Sichuan University, Chengdu, Sichuan Province, China.

### Abstract

There are unstructured abstracts (no less than 256 words) and structured abstracts (no less than 480). The specific requirements for structured abstracts are as follows:

An informative, structured abstracts of no less than 480 words should accompany each manuscript. Abstracts for original contributions should be structured into the following sections. AIM (no more than 20 words): Only the purpose should be included. Please write the aim as the form of "To investigate/study/...; MATERIALS AND METHODS (no less than 140 words); RESULTS (no less than 294 words): You should present *P* values where appropriate and must provide relevant data to illustrate how they were obtained, e.g.  $6.92 \pm 3.86$  vs  $3.61 \pm 1.67$ ,  $P < 0.001$ ; CONCLUSION (no more than 26 words).

### Key words

Please list 5-10 key words, selected mainly from *Index Medicus*, which reflect the content of the study.

### Text

For articles of these sections, original articles and brief articles, the main text should be structured into the following sections: INTRODUCTION, MATERIALS AND METHODS, RESULTS and DISCUSSION, and should include appropriate Figures and Tables. Data should be presented in the main text or in Figures and Tables, but not in both. The main text format of these sections, editorial, topic highlight, case report, letters to the editors, can be found at: [http://www.wjnet.com/2218-6247/g\\_info\\_list.htm](http://www.wjnet.com/2218-6247/g_info_list.htm).

### Illustrations

Figures should be numbered as 1, 2, 3, *etc.*, and mentioned clearly in the main text. Provide a brief title for each figure on a separate page. Detailed legends should not be provided under the figures. This part should be added into the text where the figures are applicable. Figures should be either Photoshop or Illustrator files (in tiff, eps, jpeg formats) at high-resolution. Examples can be found at: <http://www.wjnet.com/1007-9327/13/4520.pdf>; <http://www.wjnet.com/1007-9327/13/4554.pdf>; <http://www.wjnet.com/1007-9327/13/4891.pdf>; <http://www.wjnet.com/1007-9327/13/4986.pdf>; <http://www.wjnet.com/1007-9327/13/4498.pdf>. Keeping all elements compiled is necessary in line-art image. Scale bars should be used rather than magnification factors, with the length of the bar defined in the legend rather than on the bar itself. File names should identify the figure and panel. Avoid layering type directly over shaded or textured areas. Please use uniform legends for the same subjects. For example: Figure 1 Pathological changes in atrophic gastritis after treatment. A: ...; B: ...; C: ...; D: ...; E: ...; F: ...; G: ...*etc.* It is our principle to publish high resolution-figures for the printed and E-versions.

### Tables

Three-line tables should be numbered 1, 2, 3, *etc.*, and mentioned clearly in the main text. Provide a brief title for each table. Detailed legends should not be included under tables, but rather added into the text where applicable. The information should complement, but not duplicate the text. Use one horizontal line under the title, a second under column heads, and a third below the Table, above any footnotes. Vertical and italic lines should be omitted.

### Notes in tables and illustrations

Data that are not statistically significant should not be noted. <sup>a</sup>*P* < 0.05, <sup>b</sup>*P* < 0.01 should be noted (*P* > 0.05 should not be noted). If there are other series of *P* values, <sup>c</sup>*P* < 0.05 and <sup>d</sup>*P* < 0.01 are used. A third series of *P* values can be expressed as <sup>e</sup>*P* < 0.05 and <sup>f</sup>*P* < 0.01. Other notes in tables or under illustrations should be expressed as



## Instructions to authors

<sup>1</sup>F, <sup>2</sup>F, <sup>3</sup>F; or sometimes as other symbols with a superscript (Arabic numerals) in the upper left corner. In a multi-curve illustration, each curve should be labeled with ●, ○, ■, ▲, △, etc., in a certain sequence.

### Acknowledgments

Brief acknowledgments of persons who have made genuine contributions to the manuscript and who endorse the data and conclusions should be included. Authors are responsible for obtaining written permission to use any copyrighted text and/or illustrations.

## REFERENCES

### Coding system

The author should number the references in Arabic numerals according to the citation order in the text. Put reference numbers in square brackets in superscript at the end of citation content or after the cited author's name. For citation content which is part of the narration, the coding number and square brackets should be typeset normally. For example, "Crohn's disease (CD) is associated with increased intestinal permeability<sup>[1,2]</sup>". If references are cited directly in the text, they should be put together within the text, for example, "From references<sup>[19,22-24]</sup>, we know that..."

When the authors write the references, please ensure that the order in text is the same as in the references section, and also ensure the spelling accuracy of the first author's name. Do not list the same citation twice.

### PMID and DOI

Please provide PubMed citation numbers to the reference list, e.g. PMID and DOI, which can be found at <http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed> and <http://www.crossref.org/SimpleTextQuery/>, respectively. The numbers will be used in E-version of this journal.

### Style for journal references

Authors: the name of the first author should be typed in bold-faced letters. The family name of all authors should be typed with the initial letter capitalized, followed by their abbreviated first and middle initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR). The title of the cited article and italicized journal title (journal title should be in its abbreviated form as shown in PubMed), publication date, volume number (in black), start page, and end page [PMID: 11819634 DOI: 10.3748/wjg.13.5396].

### Style for book references

Authors: the name of the first author should be typed in bold-faced letters. The surname of all authors should be typed with the initial letter capitalized, followed by their abbreviated middle and first initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR) Book title. Publication number. Publication place: Publication press, Year: start page and end page.

### Format

#### Journals

*English journal article (list all authors and include the PMID where applicable)*

- 1 **Jung EM**, Clevert DA, Schreyer AG, Schmitt S, Rennert J, Kubale R, Feuerbach S, Jung F. Evaluation of quantitative contrast harmonic imaging to assess malignancy of liver tumors: A prospective controlled two-center study. *World J Gastroenterol* 2007; **13**: 6356-6364 [PMID: 18081224 DOI: 10.3748/wjg.13.6356]

*Chinese journal article (list all authors and include the PMID where applicable)*

- 2 **Lin GZ**, Wang XZ, Wang P, Lin J, Yang FD. Immunologic effect of Jianpi Yishen decoction in treatment of Pixu-diarhoea. *Shijie Huaren Xiaohua Zazhi* 1999; **7**: 285-287

*In press*

- 3 **Tian D**, Araki H, Stahl E, Bergelson J, Kreitman M. Signature of balancing selection in Arabidopsis. *Proc Natl Acad Sci USA* 2006; In press

*Organization as author*

- 4 **Diabetes Prevention Program Research Group**. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. *Hypertension* 2002; **40**: 679-686 [PMID: 12411462 PMID:2516377 DOI:10.1161/01.HYP.0000035706.28494.09]

*Both personal authors and an organization as author*

- 5 **Vallancien G**, Emberton M, Harving N, van Moorselaar RJ; Alf-One Study Group. Sexual dysfunction in 1, 274 European men suffering from lower urinary tract symptoms. *J Urol* 2003; **169**: 2257-2261 [PMID: 12771764 DOI:10.1097/01.ju.0000067940.76090.73]

*No author given*

- 6 21st century heart solution may have a sting in the tail. *BMJ* 2002; **325**: 184 [PMID: 12142303 DOI:10.1136/bmj.325.7357.184]

*Volume with supplement*

- 7 **Geraud G**, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. *Headache* 2002; **42** Suppl 2: S93-99 [PMID: 12028325 DOI:10.1046/j.1526-4610.42.s2.7.x]

*Issue with no volume*

- 8 **Banit DM**, Kaufer H, Hartford JM. Intraoperative frozen section analysis in revision total joint arthroplasty. *Clin Orthop Relat Res* 2002; **(401)**: 230-238 [PMID: 12151900 DOI:10.1097/00003086-200208000-00026]

*No volume or issue*

- 9 Outreach: Bringing HIV-positive individuals into care. *HRSA Careaction* 2002; 1-6 [PMID: 12154804]

### Books

*Personal author(s)*

- 10 **Sherlock S**, Dooley J. Diseases of the liver and biliary system. 9th ed. Oxford: Blackwell Sci Pub, 1993: 258-296

*Chapter in a book (list all authors)*

- 11 **Lam SK**. Academic investigator's perspectives of medical treatment for peptic ulcer. In: Swabb EA, Azabo S. Ulcer disease: investigation and basis for therapy. New York: Marcel Dekker, 1991: 431-450

*Author(s) and editor(s)*

- 12 **Breedlove GK**, Schorheide AM. Adolescent pregnancy. 2nd ed. Wicczorek RR, editor. White Plains (NY): March of Dimes Education Services, 2001: 20-34

*Conference proceedings*

- 13 **Harnden P**, Joffe JK, Jones WG, editors. Germ cell tumours V. Proceedings of the 5th Germ cell tumours Conference; 2001 Sep 13-15; Leeds, UK. New York: Springer, 2002: 30-56

*Conference paper*

- 14 **Christensen S**, Oppacher F. An analysis of Koza's computational effort statistic for genetic programming. In: Foster JA, Lutton E, Miller J, Ryan C, Tettamanzi AG, editors. Genetic programming. EuroGP 2002: Proceedings of the 5th European Conference on Genetic Programming; 2002 Apr 3-5; Kinsdale, Ireland. Berlin: Springer, 2002: 182-191

**Electronic journal** (list all authors)

- 15 Morse SS. Factors in the emergence of infectious diseases. Emerg Infect Dis serial online, 1995-01-03, cited 1996-06-05; 1(1): 24 screens. Available from: URL: <http://www.cdc.gov/ncidod/eid/index.htm>

**Patent** (list all authors)

- 16 **Pagedas AC**, inventor; Ancel Surgical R&D Inc., assignee. Flexible endoscopic grasping and cutting device and positioning tool assembly. United States patent US 20020103498. 2002 Aug 1

### Statistical data

Write as mean  $\pm$  SD or mean  $\pm$  SE.

### Statistical expression

Express *t* test as *t* (in italics), *F* test as *F* (in italics), chi square test as

$\chi^2$  (in Greek), related coefficient as *r* (in italics), degree of freedom as *ν* (in Greek), sample number as *n* (in italics), and probability as *P* (in italics).

### Units

Use SI units. For example: body mass, *m* (B) = 78 kg; blood pressure, *p* (B) = 16.2/12.3 kPa; incubation time, *t* (incubation) = 96 h; blood glucose concentration, *c* (glucose)  $6.4 \pm 2.1$  mmol/L; blood CEA mass concentration, *p* (CEA) = 8.6 24.5 μg/L; CO<sub>2</sub> volume fraction, 50 mL/L CO<sub>2</sub>, not 5% CO<sub>2</sub>; likewise for 40 g/L formaldehyde, not 10% formalin; and mass fraction, 8 ng/g, *etc.* Arabic numerals such as 23, 243, 641 should be read 23 243 641.

The format for how to accurately write common units and quantum numbers can be found at: [http://www.wjgnet.com/2218-6247/g\\_info\\_20100724224620.htm](http://www.wjgnet.com/2218-6247/g_info_20100724224620.htm).

### Abbreviations

Standard abbreviations should be defined in the abstract and on first mention in the text. In general, terms should not be abbreviated unless they are used repeatedly and the abbreviation is helpful to the reader. Permissible abbreviations are listed in Units, Symbols and Abbreviations: A Guide for Biological and Medical Editors and Authors (Ed. Baron DN, 1988) published by The Royal Society of Medicine, London. Certain commonly used abbreviations, such as DNA, RNA, HIV, LD50, PCR, HBV, ECG, WBC, RBC, CT, ESR, CSF, IgG, ELISA, PBS, ATP, EDTA, mAb, can be used directly without further explanation.

### Italics

Quantities: *t* time or temperature, *c* concentration, *A* area, *l* length, *m* mass, *V* volume.

Genotypes: *gyrA*, *arg 1*, *c myc*, *c fos*, *etc.*

Restriction enzymes: *EcoRI*, *HindI*, *BamHI*, *Kho I*, *Kpn I*, *etc.*

Biology: *H. pylori*, *E. coli*, *etc.*

### Examples for paper writing

**Editorial:** [http://www.wjgnet.com/2218-6247/g\\_info\\_2010072422358.htm](http://www.wjgnet.com/2218-6247/g_info_2010072422358.htm)

**Frontier:** [http://www.wjgnet.com/2218-6247/g\\_info\\_2010072422525.htm](http://www.wjgnet.com/2218-6247/g_info_2010072422525.htm)

**Topic highlight:** [http://www.wjgnet.com/2218-6247/g\\_info\\_20100724222638.htm](http://www.wjgnet.com/2218-6247/g_info_20100724222638.htm)

**Observation:** [http://www.wjgnet.com/2218-6247/g\\_info\\_2010072422802.htm](http://www.wjgnet.com/2218-6247/g_info_2010072422802.htm)

**Guidelines for basic research:** [http://www.wjgnet.com/2218-6247/g\\_info\\_20100724223311.htm](http://www.wjgnet.com/2218-6247/g_info_20100724223311.htm)

**Guidelines for clinical practice:** [http://www.wjgnet.com/2218-6247/g\\_info\\_20100724222911.htm](http://www.wjgnet.com/2218-6247/g_info_20100724222911.htm)

**Review:** [http://www.wjgnet.com/2218-6247/g\\_info\\_20100724223439.htm](http://www.wjgnet.com/2218-6247/g_info_20100724223439.htm)

**Original articles:** [http://www.wjgnet.com/2218-6247/g\\_info\\_20100724223604.htm](http://www.wjgnet.com/2218-6247/g_info_20100724223604.htm)

**Brief articles:** [http://www.wjgnet.com/2218-6247/g\\_info\\_20100724223728.htm](http://www.wjgnet.com/2218-6247/g_info_20100724223728.htm)

**Case report:** [http://www.wjgnet.com/2218-6247/g\\_info\\_20100724223843.htm](http://www.wjgnet.com/2218-6247/g_info_20100724223843.htm)

**Letters to the editor:** [http://www.wjgnet.com/2218-6247/g\\_info\\_20100724224002.htm](http://www.wjgnet.com/2218-6247/g_info_20100724224002.htm)

**Book reviews:** [http://www.wjgnet.com/2218-6247/g\\_info\\_20100724224045.htm](http://www.wjgnet.com/2218-6247/g_info_20100724224045.htm)

**Guidelines:** [http://www.wjgnet.com/2218-6247/g\\_info\\_20100724224131.htm](http://www.wjgnet.com/2218-6247/g_info_20100724224131.htm)

## SUBMISSION OF THE REVISED MANUSCRIPTS AFTER ACCEPTED

Please revise your article according to the revision policies of *WJO*. The revised version including manuscript and high-resolution image figures (if any) should be re-submitted online (<http://www.wjgnet.com/2218-6247office/>). The author should send the copyright transfer letter, responses to the reviewers, English language Grade B certificate (for non-native speakers of English) and final manuscript checklist to [wjotorhinology@wjgnet.com](mailto:wjotorhinology@wjgnet.com).

### Language evaluation

The language of a manuscript will be graded before it is sent for revision. (1) Grade A: priority publishing; (2) Grade B: minor language polishing; (3) Grade C: a great deal of language polishing needed; and (4) Grade D: rejected. Revised articles should reach Grade A or B.

### Copyright assignment form

Please download a Copyright assignment form from [http://www.wjgnet.com/2218-6247/g\\_info\\_20100724224507.htm](http://www.wjgnet.com/2218-6247/g_info_20100724224507.htm).

### Responses to reviewers

Please revise your article according to the comments/suggestions provided by the reviewers. The format for responses to the reviewers' comments can be found at: [http://www.wjgnet.com/2218-6247/g\\_info\\_20100724224317.htm](http://www.wjgnet.com/2218-6247/g_info_20100724224317.htm).

### Proof of financial support

For paper supported by a foundation, authors should provide a copy of the document and serial number of the foundation.

### Links to documents related to the manuscript

*WJO* will be initiating a platform to promote dynamic interactions between the editors, peer reviewers, readers and authors. After a manuscript is published online, links to the PDF version of the submitted manuscript, the peer-reviewers' report and the revised manuscript will be put on-line. Readers can make comments on the peer reviewer's report, authors' responses to peer reviewers, and the revised manuscript. We hope that authors will benefit from this feedback and be able to revise the manuscript accordingly in a timely manner.

### Science news releases

Authors of accepted manuscripts are suggested to write a science news item to promote their articles. The news will be released rapidly at EurekAlert/AAAS (<http://www.eurekalert.org>). The title for news items should be less than 90 characters; the summary should be less than 75 words; and main body less than 500 words. Science news items should be lawful, ethical, and strictly based on your original content with an attractive title and interesting pictures.

### Publication fee

*WJO* is an international, peer-reviewed, OA, online journal. Articles published by this journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. Authors of accepted case report must pay a publication fee. The related standards are as follows. Publication fee: 1300 USD per article; Reprints fee: 350 USD per 100 reprints, including postage cost. Editorial, topic highlights, original articles, brief articles, book reviews and letters to the editor are published free of charge.



## Events Calendar 2012

January 26-28, 2012  
Multidisciplinary Head and Neck  
Cancer Symposium  
Phoenix, AZ, United States

January 27-28, 2012  
Advanced Otology Update  
workshop  
Surat, India

February 1, 2012  
2nd Vestibular Assessment and  
Rehabilitation Therapy Course,  
University of Cape Town, South  
Africa

March 11-13, 2012  
5th International Congress on Ear  
Reconstruction  
Sydney, Australia

April 18-22, 2012  
Combined Otolaryngology Spring  
Meeting  
San Diego, CA, United States

April 26-May 28, 2012  
10th International  
Otorhinolaryngology Head and  
Neck Surgery Congress  
Ankara, Turkey

May 3-5, 2012  
12th International Conference  
on Cochlear Implants and other  
Implantable Auditor  
Baltimore, MD, United States

May 13-18, 2012  
Acoustics 2012  
Hong Kong, China

May 20-23, 2012  
11th International Congress of  
the European Society of Pediatric  
Otorhinolaryngology  
Amsterdam, The Netherlands

May 23-24, 2012  
7th Global Otology-Neurotology  
Live Surgical Broadcast, Europe  
Utrecht, The Netherlands

June 3-7, 2012  
9th International Conference on  
Cholesteatoma and Ear Surgery  
Nagasaki, Japan

July 25-27, 2012  
Frontiers in Otorhinolaryngology  
Conference  
Melbourne, Australia

July 26-28, 2012  
Open Forum (formerly Sinus Forum)  
New York, NY, United States